Mirum Pharmaceuticals Inc (MIRM)
Mirum Pharmaceuticals, Inc. is a NASDAQ-listed common equity in the healthcare sector focused on biopharmaceutical development and commercialization for rare and orphan diseases. The company’s lead approved therapy is LIVMARLI (maralixibat), an oral and minimally absorbed IBAT inhibitor approved in the United States and internationally for cholestatic pruritus in patients with Alagille syndrome. Mirum also commercializes Cholbam, a cholic acid capsule used for certain bile acid synthesis disorders and as adjunctive treatment in selected peroxisomal disorders, as well as Chenodal, which is approved for radiolucent gallbladder stones and is being studied for cerebrotendinous xanthomatosis. Its development pipeline includes Volixibat for adult cholestatic liver diseases, Brelovitug for chronic HDV infection, and MRM-3379 for fragile X syndrome. Founded in 2018, the company is headquartered in Foster City, California.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-MIRM
|
$92.85
|
-20.5% Downside
|
Overvalued
|
$146.50
|
25.4% Upside
|
Undervalued
|
Fair
|
—
|
—
|
—
|
0.0%
|
July 30, 2026
|
-8.9x
|
29.3x
|
12.5x
|
7.112 B
|
7.042 B
|
4.4%
|
86.0%
|
4.4
|
—
|
21.6%
|
